ISSN 1662-4009 (online)

ey0018.3-16 | Reviews | ESPEYB18

3.16. New therapeutic horizons for Graves' hyperthyroidism

LC Lane , TD Cheetham , P Perros , SHS Pearce

Endocr Rev. 2020;41:873–84. doi: 10.1210/endrev/bnaa022.Over the last decades, the treatment of Graves’ disease has been limited to antithyroid drugs, radioactive iodine ablation or surgery. Especially in the paediatric age group, all three therapeutic options have their advantages and side effects.New therapeutic options focus on the immune-pathophysiology ...

ey0019.3-12 | Autoimmune Thyroid Disease | ESPEYB19

3.12. The 2022 European Thyroid Association guideline for the management of pediatric Graves' disease

CF Mooij , TD Cheetham , FA Verburg , A Eckstein , SH Pearce , J Leger , ASP van Trotsenburg

Eur Thyroid J. 2022 Jan 1;11(1):e210073. doi: 10.1530/ETJ-21-0073. PMID: 34981748The 2022 European Thyroid Association Guidelines for the management of Graves’ disease in the pediatric age group is an important document summarizing all aspects of the disease, ranging from diagnosis, medical treatment with its advantages and side effects, definitive treatment by thyroidectomy or radioiodine a...

ey0018.3-12 | Clinical studies | ESPEYB18

3.12. Randomised trial of block and replace vs. dose titration thionamide in young people with thyrotoxicosis

CL Wood , M Cole , M Donaldson , DB Dunger , R Wood , N Morrison , JNS Matthews , SHS Pearce , TD Cheetham

Eur J Endocrinol. 2020;183:637–645. doi: 10.1530/EJE-20-0617.This study provides for the first time clear evidence that the block and replace (BR) strategy (combination of carbimazole plus levothyroxine) is not superior to the carbimazole dose titration (DT) strategy for treatment of paediatric Graves’ disease.Wood et al. present the first randomized c...